Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of Obeldesivir in Children and Adolescents With COVID-19
2023-503282-27-00Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of obeldesivir in coronavirus disease 2019 (COVID-19), sponsored by Gilead Sciences. Primary endpoints: PK parameters for GS-441524 (ODV metabolite), Incidence of treatment-emergent adverse events and 1 more. Started Dec 2023; status: completed.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-503282-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503282-27-00.